Concomitant Primary Hyperparathyroidism in Patients with Multiple Myeloma: A Possible Link?

Area of Science:

• Endocrinology
• Oncology
• Bone Metabolism

Background:

• Hypercalcemia is common in active multiple myeloma (MM), often associated with extensive bone disease.
• Primary hyperparathyroidism (PHPT) is a frequent cause of non-neoplastic hypercalcemia, linked to osteoporosis and fractures.
• Preclinical data suggest parathyroid hormone (PTH) may negatively affect bone disease and MM progression.

Observation:

• This study presents 4 cases of active MM patients with hypercalcemia and elevated or inappropriately normal PTH levels.
• Analysis revealed a lack of PTH receptor 1 and PTH-related peptide expression on CD138+ cells in these MM patients.
• This indicates a potential paracrine role for PTH in MM, rather than a direct pro-tumoral effect.

Findings:

• The absence of direct PTH receptor expression on myeloma cells suggests PTH's influence may be indirect.
• The findings challenge the rarity of concomitant MM and PHPT diagnoses.
• PTH's role in MM pathogenesis warrants further investigation.

Implications:

• Concomitant MM and PHPT may be underdiagnosed and should be considered in the clinical management of hypercalcemic MM patients.
• Understanding the interplay between PTH and MM can lead to improved treatment strategies for bone complications and disease control.
• Further research is needed to elucidate the precise paracrine mechanisms of PTH in multiple myeloma.